Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting.
Manzoni
Paolo
P
Leonessa
MariaLisa
M
Farina
Daniele
D
Gomirato
Giovanna
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D007153:Immunologic Deficiency Syndromes / Q000150:complications* / Q000276:immunology; D015994:Incidence; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal; D007558:Italy / Q000453:epidemiology; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses; D012307:Risk Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab